List view / Grid view
29 February 2012 | By Helen Difford, Editor of European Pharmaceutical Review
Helen Difford, Editor of European Pharmaceutical Review, looks at the reasons behind recent mergers and acquisitions within the pharmaceutical sector...
29 February 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has expanded its biopharmaceutical development & manufacturing capabilities...
29 February 2012 | By kdm communications limited
Syrris has created the unique Atlas Syringe Pump XL...
29 February 2012 | By Novartis
Novartis named Brian McNamara to the position of Division Head of Novartis OTC (Over-the-Counter), effective immediately...
29 February 2012 | By Pfizer
The U.S. FDA has extended the action date by three months for the NDA for Eliquis® (apixaban)...
29 February 2012 | By Abbott
Abbott and Galapagos have entered into a global collaboration...
29 February 2012 | By Novartis
Results of the COMFORT-I and COMFORT-II trials show INC424 significantly reduced disease burden in patients with myelofibrosis...
28 February 2012 | By Eli Lilly and Company
Lilly award programs also further research and development investment in Europe...
28 February 2012 | By
Dosing enhancements may improve treatment experience for patients receiving AVONEX® (interferon beta-1a) for MS...
28 February 2012 | By Biogen Idec
EMA submission anticipated within the coming days...
28 February 2012 | By Amgen
Amgen & European Schoolnet launched “Amgen Science Teacher Training Initiative”...
28 February 2012 | By Daiichi Sankyo Co., Ltd
The Board of Directors of Ranbaxy Laboratories Limited, took on record the audited results for the Quarter and Year ended December 31, 2011...
28 February 2012 | By Bristol-Myers Squibb Company
First project will be to develop and implement protocol for Phase II study in IPF...
28 February 2012 | By H. Lundbeck A/S (Lundbeck)
Lundbeck acquires Paion's remaining rights to desmoteplase for EUR 20.1 million thereby further strengthening the control over desmoteplase...
28 February 2012 | By Merck
Merck received a Warning Letter from the U.S. FDA relating to JANUVIA (sitagliptin) and JANUMET (sitagliptin/metformin HCl)...
